Stay updated with breaking news from Molecular Testing Hcc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dr R. Katie Kelley explains the design and results of the phase 3 CELESTIAL study investigating single-agent cabozantinib for the treatment of advanced hepatocellular carcinoma.
R. Katie Kelley, MD, comments on the safety and efficacy data from the retrospective analysis of the CELESTIAL study in advanced hepatocellular carcinoma.
Key opinion leaders discuss the sequencing of systemic therapy options for patients with advanced HCC.
Experts review data from IMbrave050 on the potential role of atezolizumab plus bevacizumab in the adjuvant setting for HCC.
The panel explains the Child-Pugh scoring system and how staging and liver function impact treatment decisions for patients with HCC.